Research found that men with periodontal disease had a 63% higher risk of pancreatic cancer, while those who reported recent tooth loss showed a 2.5-fold increase in risk. Obesity also impairs immune responses to vaccines.
Researchers developed a potential vaccine targeting HER-2/neu overexpression in early stage breast cancer, yielding promising results for women at high-risk. The study found that nearly all patients exhibited an immune response and many developed protein antibodies to fight the cells.
A study found that only 40% of US women have ever heard of HPV, and fewer still know about its connection to cervical cancer. The public needs education on HPV and cervical cancer to make informed health care choices, researchers concluded.
Scientists at the American Association for Cancer Research have developed a novel method to detect DNA methylation in exhaled breath, which may help predict lung cancer development. The test has also shown promise in identifying patients with pancreatic cancer, raising hopes for early detection and treatment.
Dr. Stephen S. Hecht is recognized for over three decades of research on tobacco carcinogenesis, identifying nicotine's role in lung cancer formation. His work has led to the development of biomarkers for exposure to tobacco smoke and informed public policies on smoking restriction.
A recent study by the American Association for Cancer Research found that HPV tests are a better predictor of cervical cell abnormalities than Pap smears, particularly in older women. The researchers discovered that HPV-positive women aged 40 and above had a significantly higher risk of developing cervical cancer within 10 years.
A study found that grape seed extract significantly inhibits the growth of colorectal tumors in both human cells and mice. The extract works by increasing the availability of a critical protein called Cip1/p21, which freezes the cell cycle and often pushes cancer cells to self-destruct.
A synthetic vitamin E derivative, á-TEA, has been shown to inhibit the spread of aggressive mammary cancer in mice when mixed into their food. The study found a 4.8-fold reduction in tumors that spread to the lungs, suggesting potential use as a dietary supplement for treating human metastatic breast cancer.
Margaret Foti, AACR CEO, receives the Association of American Cancer Institutes Distinguished Service Award for her leadership and advocacy in advancing cancer research. The AACR has grown to over 24,000 members under her tenure, and she has launched several high-quality journals in the field.
A new test, OncoPlan, has been developed to predict which breast cancer patients are likely to benefit from chemotherapy. The test measures the levels of two proteins that play a role in cancer growth and survival.
A potential diagnostic marker indicates anti-angiogenic drugs' effectiveness by measuring a decrease in circulating endothelial cells. Anti-angiogenic drugs target tumor blood vessels, starving them of oxygen and nutrients.
Researchers found that patients with advanced squamous cell carcinoma of the head and neck whose tumor samples over-expressed p53 protein were significantly more likely to respond to Advexin therapy than those with low p53 protein. The study suggests that p53 overexpression may be a predictive biomarker for Advexin efficacy.
Researchers found that a single genetic assay can predict response to different targeted therapies in gastrointestinal stromal tumors. Patients with exon 9 mutations or wild-type genes may benefit more from Sutent, while those with exon 11 mutations may require longer Gleevec treatment.
Researchers found a correlation between tNOX levels and tumor burden in prostate cancer patients, suggesting its potential as a reliable biomarker. The study showed that tNOX levels increased with disease progression and were more uniform in terms of disease severity than PSA scores.
A new protocol using the protein tNOX has shown promise in detecting lung cancer early in smokers and nonsmokers. The test involves measuring levels of tNOX in the blood, with low false positive rates, making it a potential screening tool for early detection.
A new technology can detect one malignant cell in a typical blood sample, enabling early adjustment of treatment to target spreading cancer. This diagnostic tool has a 97% specificity and may revolutionize the prevention of cancer death.
A new study found that raloxifene significantly reduces breast cancer risk in postmenopausal women, with a 58% reduction for those without a family history and an 89% reduction for those with a family history. The researchers are puzzled by why protection seems greatest in genetically predisposed women.
A new biomarker predicting survival in colorectal carcinomas has been discovered, with thymidylate synthase levels in the nucleus and cytoplasm identified as critical markers. The ratio of nuclear to cytoplasmic TS levels also predicts decreased survival, revealing a new potential biomarker for patients with worse prognosis.
A study has identified molecular markers in RNA and DNA that can detect small metastases from ocular melanoma, allowing for early intervention. Fine needle biopsy is a feasible method to accurately detect these markers, enabling clinicians to identify high-risk patients who may benefit from targeted treatments.
A new protein in blood serum, human aspartyl beta-hydroxylase (HAAH), has shown promise as a sensitive and specific biomarker for early detection of prostate cancer. HAAH is overexpressed in at least 20 types of cancer and has been linked to tumor growth and invasiveness.
Two genes, REG1A and EXTL3, are prognostic markers for colorectal cancer recurrence. REG1A expression levels correlate with disease-free survival, while EXTL3 is a predictor of patient outcome.
Researchers found that patients with tumors producing high levels of VEGF and its receptor benefit most from targeted treatments. The study identified a correlation between tumor mutational analysis, VEGF expression, and treatment response.
Researchers developed a new method to detect oncogene mutations in human cancers, which could be used in real-time to match patients with available targeted therapies. The technique uses high-throughput mass spectrometry-based genotyping and was validated in over 1,000 tumors, representing 15 different cancer types.
A small subset of glioma cells expressing higher levels of VEGF promote tumor blood vessel formation, making them a potential target for new therapies against intractable brain tumors. Targeting these cancer stem cells may block angiogenesis and prevent tumor growth.
Eleven researchers received grants to accelerate the discovery and development of new agents for treating metastatic colon cancer. The study aims to identify mechanisms in colon cancer that make tumor cells resistant to apoptosis, as well as develop combination drug therapies to reverse the apoptotic defect.
Researchers found that pomegranate juice reduced PSA levels by 30% in patients with recurrent prostate cancer, slowing the doubling time of PSA levels. The antioxidant ellagic acid in pomegranate juice was also shown to increase nitric oxide production and induce programmed cell death.
Researchers have identified a biological marker that predicts persistent fatigue in breast cancer survivors, attributed to inflammation. The biomarker combines immune response elements, including interleukin-6 receptor and T cells with CD69 protein.
Researchers have identified a potential new treatment for malignant gliomas using bortezomib, which targets the NF-kB pathway to induce cell death. This discovery builds on previous studies showing that selective estrogen receptor modulators (SERMs) can also induce cell death in brain cancers.
Researchers discovered four protein biomarkers that can predict death from colorectal cancer independent of stage or location. A micro-RNA signature also predicts colon cancer development by regulating gene expression and cellular pathways.
Regular use of antihistamines has been linked to a higher risk of developing low-grade and anaplastic astrocytomas, two types of brain tumors. Conversely, anti-inflammatory medications may help protect against glioblastoma, a more deadly type of tumor.
Research suggests that Vitamin D, along with outdoor activities and diet, may lower breast cancer risk. Studies found significant reductions in breast cancer among individuals exposed to high levels of Vitamin D, particularly during adolescence.
Researchers found that former smokers have higher CC10 levels than current smokers, which may help explain the lower risk of lung cancer among quitters. Additionally, first-degree relatives of never-smoking lung cancer patients are at increased risk of cancer and early diagnosis compared to healthy never-smokers.
Panitumumab significantly improves progression-free survival and disease control in patients with mCRC, with a median duration of response of 17 weeks. The treatment was well-tolerated, with few major adverse reactions.
Researchers have developed novel diagnostic tests for lung cancer using airway gene expression assays, which identified three times as many early-stage cancers as conventional bronchoscopy. Genetic signatures from epithelial cells complement clinical results to diagnose 95% of patients with lung cancer.
Studies confirm celecoxib reduces the formation of large intestinal adenomas and incidence of pre-malignant tumors in high-risk patients. Celecoxib also showed reduced risk of advanced neoplasms, severe dysplasia, or invasive cancer.
Dasatinib has shown promise in treating leukemia patients resistant to standard therapies, with 93% complete hematologic response and 45% major cytogenetic response. However, relapses have occurred in certain patient groups due to dasatinib-resistant BCR-ABL mutations.
Research at a public hospital found that African-American and white women have similar prognostic profiles for estrogen receptor and tumor grade. Low economic standing is linked to poor outcomes, regardless of racial background. Socioeconomic status, not biological factors, may contribute to breast cancer disparities.
Dr. Bernard Fisher's pioneering research on tumor metastasis and clinical trials has transformed the management of breast cancer. His systematic studies revealed that a combination of lumpectomy and radiation therapy is equally effective as total mastectomy, changing the way physicians approach patient care.
The American Association for Cancer Research (AACR) is launching a new magazine, CR, to address the public's need for understandable information about cancer research and policy. The magazine aims to put a human face on cancer research by sharing stories of survivors and their experiences.
AACR Public Service Awards recognize Sherry Lansing and Janet Woodcock's dedication to advancing cancer research. Lansing, former Paramount CEO, has raised millions for cancer research through her non-profit advocacy group Stop Cancer, while Woodcock, FDA deputy commissioner, streamlines cancer medicine oversight.
The American Association for Cancer Research (AACR) has conferred its highest honors to several scientists for their groundbreaking contributions to cancer research. Carlo Croce and Wiliam Kaelin received awards for their pioneering work in leukemia and lymphoma research, while Julian Adams was recognized for his discovery of the first...
The American Association for Cancer Research (AACR) offers several awards and fellowships to support promising cancer scientists, including the AACR-GERTRUDE B. ELION CANCER RESEARCH AWARD, CAREER DEVELOPMENT AWARDS, and AACR-Cancer Research and Prevention Foundation Career Development Awards in Translational or Prevention Lung Cancer ...
Tadatsugu Taniguchi is honored with the international award for his major scientific discovery in basic cancer research, elucidating cytokine gene families and transcription factors. He made significant contributions to our understanding of immune defense mechanisms and cancer therapy.
Dr. Olopade receives AACR-Minorities in Cancer Research-Jane Cooke Wright Lectureship for her pre-eminent research on breast cancer prevention and detection. Her work has led to strategies for identifying novel BRCA-1 mutations in African-American families.
The American Association for Cancer Research (AACR) has expanded its scholarship program to promote inclusivity in cancer research, supporting early-career scientists from underrepresented groups. The program provides financial support for conference attendance and research expenses.
Researchers found that capsaicin induced apoptosis in human prostate cancer cells, reducing tumor size and proliferation. The study suggests capsaicin may slow prostate tumor development and production of PSA protein.
A new screening method using cells in lung mucus can predict tumor development up to 18 months in advance. The test identified 65% of individuals who later developed symptoms of lung cancer, but also misidentified 35% of cancer-free participants.
Robert A. Weinberg's work on human oncogenes led to understanding cancer's mechanisms of invasion and progression. Angela M. Hartley Brodie developed aromatase inhibitors to prevent breast cancer recurrence in postmenopausal women.
Researchers found that Botox injected into mouse tumors opened their cellular vasculature, allowing effective destruction of previously resistant cancer cells. This approach aims to alleviate tumor hypoxia, making them more susceptible to treatment.
A group of 40 leading cancer scientists proposes a Human Epigenome Project to map the chemical modifications to DNA that comprise the epigenetic code. The project aims to unlock the epigenomic information stored in the genome for the benefit of human health.